ABSTRACT
Objective：An inertial sensor-based motion capture system for rehabilitation therapy is feasible due to its simple measurement methods. However, a standard value must be used to evaluate or diagnose pathological gait kinematically. This study aimed to set a standard value by determining the averaged spatial-temporal parameter (STP) and range of motion (ROM) during gait in healthy participants.Methods：This study included 177 healthy individuals, who were grouped into six groups according to gender (male and female) and age (young, middle, and old). All participants walked under two speed conditions (NORMAL or FAST) and the gait was captured with an inertial sensor-based motion capture system. Eight types of STP and fourteen types of ROM were calculated.Results：Of the 132 variables (22 variables × 2 sexes × 3 ages), 123 variables for NORMAL and 112 variables for FAST followed the normal distribution. A main effect of age on walking velocity for FAST was noted but not for NORMAL. The middle and old ages depended on an increased cadence for maintaining walking velocity. Ankle and hip ROMs in the old were smaller than that in the young, and these differences were demonstrated more so during the FAST condition. There were gender differences in hip ROMs (men had greater internal-external rotation and women had greater flexion-extension).Conclusion：The standard value can be determined from variables in gait assessment, for young to elderly, and gender-specific.
ABSTRACT
This study aimed to estimate the cost-effectiveness of pregabalin treatment for neuropathic pain.<br>Design:Long-term simulations based on state transition models.<br>Methods:We examined the cost-effectiveness of pregabalin for treatment of three common peripheral neuropathic pains, postherpetic neuralgia(PHN), painful diabetic peripheral neuropathy(DPN), and radiculopathy, using the incremental cost-effectiveness ratio(ICER). We used quality-adjusted life years(QALYs)as an index of effectiveness, and also estimated medical costs. For PHN and DPN, we constructed state transition models comprising two states, with and without pregabalin treatment, and performed 52-week simulations. The pain scores reported in Japanese phaseIII studies were used to set patients' weekly pain scores. The results of utility surveys conducted overseas were used as utility scores, while values randomly sampled from probability distributions were used to set weekly pain scores and drop-out rates. In base-case analyses, we performed 1000 1st-order Monte Carlo simulations using 1000 values randomly sampled from probability distributions, and calculated QALYs and medical costs for 52 weeks for each group. For radiculopathy, the ICER was calculated from changes in QALYs for 12 weeks reported overseas and medical costs estimated separately for the identical period.<br>Results:The ICERs for PHN, DPN, and radiculopathy were 1,116,886 Yen/QALY, 1,100,420 Yen/QALY, and 1,095,943 Yen/QALY, respectively, which were well below the upper limits of ICER ranges for treatments considered cost-effective. There were no cases in which ICERs obtained from scenario and sensitivity analyses differed significantly.<br>Conclusion:Pregabalin was shown to be cost-effective treatment for neuropathic pain.